Latest news
Prevention Is Now Alzheimer’s Hardest Trial
Roche’s PrevenTRON trial moves trontinemab into cognitively unimpaired people at high biological risk of Alzheimer’s decline. The science is bold. The ethics and access questions are even bigger.
Tissue-Agnostic Medicine Has a New Proof Point
Lung Cancer May Be Entering the Chemo-Replacement Fight
A Blood Test Can See Risk. Policy Cannot Yet Hold It.
Britain Has A £1 Billion Pandemic Plan.
AI can flag hidden cardiac risk. The dangerous part is what health systems do next
Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence
IPM Brief – Issue 13 | The Test Is Becoming the Politics
Breast Cancer Gets a New PI3K Pathway Option.
Bladder Cancer Surgery Just Became a System Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.